Foundation Frontiers: A Medical Education Webinar Jun 13

Foundation Frontiers: A Medical Education Webinar   
Fusion Detection in Advanced Non-Small Cell Lung Cancer: Stay up to Date

Thursday, June 13, 2024 
1 - 2 p.m. Eastern; noon - 1 p.m. Central; 10 - 11 a.m. Pacific

In non-small cell lung cancer (NSCLC), targetable driver alterations include ALK*, RET**, and ROS1*** fusions. DNA-based and RNA-based next-generation sequencing each have advantages and drawbacks for detecting gene fusions. In this webinar, expert speakers will present their perspectives on fusion detection in NSCLC.  

Attendees Will Learn:

• Summary of currently approved therapies for fusions in NSCLC.  
• Methods and recommendations for fusion detection with comprehensive genomic profiling. 
• The pros and cons of DNA and RNA sequencing for fusion detection.  
• About fusion detection in the context of a hypothetical patient case.   

Speakers: 

Mark Socinski, MD  
Executive Director (Thoracic Cancer), Medical Oncologist   
AdventHealth Cancer Institute  
Orlando, FL  

Holli Dilks, PhD  
Senior Director, Global Head of Field Medical 
Foundation Medicine  
Boston, MA

* Anaplastic lymphoma kinase (ALK) 
** rearranged during transfection (RET) 
*** ROS proto-oncogene 1, receptor tyrosine kinase (ROS1)